- Home
- CRVO vs ASRT Comparison
CRVO vs ASRT Comparison
Compare CRVO & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- ASRT
- Stock Information
- Founded
- CRVO 2001
- ASRT 1995
- Country
- CRVO United States
- ASRT United States
- Employees
- CRVO N/A
- ASRT N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- ASRT Health Care
- Exchange
- CRVO Nasdaq
- ASRT Nasdaq
- Market Cap
- CRVO 67.4M
- ASRT 79.1M
- IPO Year
- CRVO N/A
- ASRT 1997
- Fundamental
- Price
- CRVO $10.12
- ASRT $0.81
- Analyst Decision
- CRVO Strong Buy
- ASRT Strong Buy
- Analyst Count
- CRVO 6
- ASRT 1
- Target Price
- CRVO $17.60
- ASRT $3.00
- AVG Volume (30 Days)
- CRVO 820.1K
- ASRT 289.6K
- Earning Date
- CRVO 08-08-2025
- ASRT 08-11-2025
- Dividend Yield
- CRVO N/A
- ASRT N/A
- EPS Growth
- CRVO N/A
- ASRT N/A
- EPS
- CRVO N/A
- ASRT N/A
- Revenue
- CRVO $7,776,968.00
- ASRT $117,099,000.00
- Revenue This Year
- CRVO N/A
- ASRT N/A
- Revenue Next Year
- CRVO N/A
- ASRT $11.91
- P/E Ratio
- CRVO N/A
- ASRT N/A
- Revenue Growth
- CRVO N/A
- ASRT N/A
- 52 Week Low
- CRVO $1.80
- ASRT $0.51
- 52 Week High
- CRVO $20.63
- ASRT $1.38
- Technical
- Relative Strength Index (RSI)
- CRVO 65.00
- ASRT 66.13
- Support Level
- CRVO $9.11
- ASRT $0.71
- Resistance Level
- CRVO $9.96
- ASRT $0.86
- Average True Range (ATR)
- CRVO 0.79
- ASRT 0.03
- MACD
- CRVO 0.06
- ASRT 0.01
- Stochastic Oscillator
- CRVO 90.31
- ASRT 70.69
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.